Free Access
Vet. Res.
Volume 34, Number 2, March-April 2003
Page(s) 177 - 184
How to cite this article Vet. Res. (2003) 177-184
  1. Aguillón J.C., Ferreira V., Núñez E., Paredes L., Molina M.C., Colombo A., Hermosilla T., Ferreira A., Immunomodulation of LPS ability to induce the local Shwartzman reaction, Scand. J. Immunol. 44 (1996) 551-555 [PubMed].
  2. Bagby G.J., Plessala K.J., Wilson L.A., Thompson J.J., Nelson S., Divergent efficacy of antibody to tumor necrosis factor-a in intravascular and peritonitis models of sepsis, J. Infect. Dis. 163 (1991) 83-88 [PubMed].
  3. Beutler B., Milsark I.W., Cerami A.C., Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin, Science 229 (1985) 869-871 [CrossRef].
  4. Beutler B., Cerami A., Cachectin and tumor necrosis factor as two sides of the same biological coin, Nature (London) 320 (1986) 584 [CrossRef].
  5. Cerami A., Beutler B., The role of cachectin/ TNF in endotoxic shock and cachexia, Immunol. Today 9 (1988) 28-31 [CrossRef] [PubMed].
  6. Elliot M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Woody J.N., Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-$\alpha$, Arthritis Rheum. 36 (1993) 1681-1690 [PubMed].
  7. Fisher C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., Abraham E., Schein R.M., Benjamin E., Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein, N. Engl. J. Med. 334 (1996) 1697-1702 [CrossRef] [PubMed].
  8. Flick D.A., Gifford E., Comparison of in vitro cell cytotoxic assays for tumor necrosis factor, J. Immunol. Methods 68 (1984) 167-175 [CrossRef] [PubMed].
  9. Köhler G., Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256 (1975) 495-498 [CrossRef] [PubMed].
  10. Lawrence C.E., Callanan J.J., Jarrett O., Decreased mitogen responsiveness and elevated tumor necrosis factor production in cats shortly after feline immunodeficiency virus infection, Vet. Immunol. Immunopathol. 35 (1992) 51-59 [PubMed].
  11. Le J., Vilcek. J., Tumor necrosis factor and Interleukin-1: Cytokines with multiple overlapping biological activities, Lab. Invest. 56 (1987) 234-248 [PubMed].
  12. Lorenz H.M., Antoni C., Valerius T., Repp R., Grünke M., Schwerdtner N., Nüblein H., Woody J., Kalden J.R., Manger B., In vivo blockade of TNF-$\alpha$ by intravenous infusion of a chimeric monoclonal TNF-$\alpha$ antibody in patients with rheumatoid arthritis, J. Immunol. 156 (1996) 1646-1653 [PubMed].
  13. Louis E., Franchimont D., Piron A., Gevaert Y., Schaaf-lafontaine N., Roland S., Mahieu P., Malaise M., De Groote D., Louis R., Belaiche J., Tumour necrosis factor (TNF) gene polymorphism influences TNF-$\alpha$ production in lipopolysaccharide (LPS)-stimula- ted whole blood cell culture in healthy humans, Clin. Exp. Immunol. 113 (1998) 401-406 [PubMed].
  14. Luheshi G., Rothwell N., Cytokines and Fever, Int. Arch. Allergy Immunol. 109 (1996) 301-307 [PubMed].
  15. Ma J., Kennedy-Stoskopff S., Sellon R., Tonkonogy S., Hawkins E.C., Tompkins M.B., Tompkins W.A., Tumor necrosis factor-alpha responses are depressed and interleukin-6 responses unaltered in feline immunodeficiency virus infected cats, Vet. Immunol. Immunopathol. 46 (1995) 35-50 [PubMed].
  16. Maini R.N., Elliot M.J., Brennan F.M., Williams R.O., Chu C.Q., Paleolog E., Charles P.J., Taylor P.C., Feldman M., Monoclonal anti-TNF-$\alpha$ antibody as a probe of phatogenesis and therapy of rheumatoid disease, Immunol. Rev. 144 (1995) 195-223 [PubMed].
  17. Molloy G., Mannik V., Rodrick L., Cytokines, sepsis and immunomodulation, Br. J. Surg. 80 (1993) 289-297 [PubMed].
  18. Molvig J., Baek P., Christensen P., Manogue K., Vlassara H., Platz H., Nielsen S., Svensen T., Nerup J., Endotoxin-stimulated human monocyte secretion of interleukin 1, tumor necrosis factor-alpha and prostaglandin E2 shows interindividual differences, Scand. J. Immunol. 27 (1988) 705-716 [PubMed].
  19. Myers M.J., Murtaugh M.P., Cytokine in Animal Health and Disease, New York, Marcel Dekker, Inc., 1995.
  20. Old L.J., Tumor necrosis factor (TNF), Science 230 (1985) 630-632 [CrossRef].
  21. Pennica D., Nedwin G.E., Hayflick J.S., Seeburg P.H., Derynck R., Palladino M.A., Kohr W.J., Aggarwal B.B., Goeddel V., Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin, Nature 312 (1984) 20-27 [CrossRef].
  22. Rink L., Kirchner H., Recent progress in the tumor necrosis factor-$\alpha$ Field, Int. Arch. Allergy Immunol. 111 (1996) 199-209 [PubMed].
  23. Taveira Da Silva A., Kaulbach H., Chuidian F.S., Lambert D.R., Suffredini A.F., Danner R.L., Brief report: shock and multiple-organ dysfunction after self-administration of salmonella endotoxin, N. Engl. J. Med. 328 (1993) 1457-1460 [CrossRef] [PubMed].
  24. Vassalli P., The pathophysiology of tumor necrosis factor, Ann. Rev. Immunol. 10 (1992) 411-452.
  25. Wilson B.M., Severn A., Rapson N.T., Chana J., Hopkins P., A convenient human whole blood culture system for studying the regulation of tumour necrosis factor release by bacterial lipopolysaccharide, J. Immunol. Methods 139 (1991) 223-240 [CrossRef] [PubMed].